Cheryl Scott Net Worth

The estimated Net Worth of Cheryl Scott is at least $1.24 Milhão dollars as of 28 June 2024. Ms. Scott owns over 1,462 units of Progyny Inc stock worth over $231,244 and over the last 9 years she sold PGNY stock worth over $726,470. In addition, she makes $281,940 as Independent Director at Progyny Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Scott PGNY stock SEC Form 4 insiders trading

Cheryl has made over 9 trades of the Progyny Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 1,462 units of PGNY stock worth $41,506 on 28 June 2024.

The largest trade she's ever made was selling 6,405 units of Progyny Inc stock on 11 June 2021 worth over $124,193. On average, Cheryl trades about 977 units every 104 days since 2015. As of 28 June 2024 she still owns at least 10,098 units of Progyny Inc stock.

You can see the complete history of Ms. Scott stock trades at the bottom of the page.

Cheryl Scott biography

Cheryl M. Scott serves as Independent Director of the Company. Ms. Scott has served since July 2016 as the Main Principal of the McClintock Scott Group. From June 2006 to July 2016, Ms. Scott served as Senior Advisor to the Bill & Melinda Gates Foundation. Previously, she served as President and Chief Executive Officer of the Seattle-based Group Health Cooperative for eight years. Ms. Scott has served as a member of the board of directors of Evolent Health, Inc. since November 2015. She also currently serves on a variety of private and not-for-profit boards. She was a member of the board of directors of Recreational Equipment Incorporated (REI) from 2005 to 2017, and served as the board chairperson from 2015 to 2017. Ms. Scott received her bachelor’s degree in communications and master’s degree in health management from the University of Washington, and is currently a Clinical Professor of Health Services at the University of Washington.

What is the salary of Cheryl Scott?

As the Independent Director of Progyny Inc, the total compensation of Cheryl Scott at Progyny Inc is $281,940. There are 7 executives at Progyny Inc getting paid more, with David Schlanger having the highest compensation of $4,964,200.

How old is Cheryl Scott?

Cheryl Scott is 70, she's been the Independent Director of Progyny Inc since 2019. There are 1 older and 15 younger executives at Progyny Inc. The oldest executive at Progyny Inc is Norman Payson, 72, who is the Independent Director.

What's Cheryl Scott's mailing address?

Cheryl's mailing address filed with the SEC is C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK, NY, 10018.

Insiders trading at Progyny Inc

Over the last 5 years, insiders at Progyny Inc have traded over $949,717,514 worth of Progyny Inc stock and bought 76,923 units worth $999,999 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Plc Gsk, eGp A, Llcbonderman Davidcou.... On average, Progyny Inc executives and independent directors trade stock every 4 days with the average trade being worth of $2,005,422. The most recent stock trade was executed by Michael E Sturmer on 16 July 2024, trading 9,030 units of PGNY stock currently worth $270,900.

What does Progyny Inc do?

progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.

Complete history of Ms. Scott stock trades at Evolent Health Inc e Progyny Inc

Progyny Inc executives and stock owners

Progyny Inc executives and other stock owners filed with the SEC include:

• David Schlanger,
  Chief Executive Officer, Director
• Peter Anevski,
  President, Chief Operating Officer
• David J. Schlanger,
  Exec. Chairman
• Peter Anevski,
  Chief Exec. Officer
• Mark S. Livingston,
  Chief Financial Officer
• Jennifer Bealer,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Park,
  Independent Director
• Cheryl Scott,
  Independent Director
• Kevin Gordon,
  Independent Director
• Beth Seidenberg,
  Independent Chairman of the Board of Directors
• Norman Payson,
  Independent Director
• Frederick Cohen,
  Independent Director
• Roger Holstein,
  Director
• Malissia Clinton,
  Director
• Lisa Greenbaum,
  Executive Vice President, Chief Client Officer
• Jennifer Bealer,
  Executive Vice President, General Counsel
• Mark Livingston,
  Chief Financial Officer, Principal Accounting Officer
• Julie Stadlbauer,
  Exec. VP of Strategic Sales & Partnerships
• Michael Sturmer,
  Pres
• Cassandra Pratt,
  Sr. VP of People
• Risa Fisher,
  Exec. VP of Marketing & Communication
• James Hart,
  VP of Investor Relations
• Fred E Cohen,
  Director
• Xiii Associates, Llc Kpcb,
  10% owner
• Karin Ajmani,
  EVP, Chief of Strategic Dev.
• Perkins Caufield & Byers Xi...,
  
• Plc Gsk,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Lloyd H Dean,
  Director
• Gp A, Llcbonderman Davidcou...,
  
• Allison Swartz,
  EVP, GC
• Michael E Sturmer,
  PRESIDENT